Noscapine
- Generic Name
- Noscapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23NO7
- CAS Number
- 128-62-1
- Unique Ingredient Identifier
- 8V32U4AOQU
- Indication
Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.
- Associated Conditions
- Common Cold, Cough, Respiratory Diseases
- Associated Therapies
- Airway secretion clearance therapy
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Cougar Biotechnology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00912899
- Locations
- 🇺🇸
Columbia Presbyterian Hospital, New York City, New York, United States
🇺🇸St. Vincent's Comprehensive Cancer Center, New York City, New York, United States
🇺🇸UCLA, Los Angeles, California, United States
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 12
- Registration Number
- NCT00183950
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath